NCT00611403View on ClinicalTrials.gov

Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

137

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

June 30, 2009

Conditions
Dry Eye Syndromes
Interventions
DRUG

Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)

Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery

DRUG

Artificial Tears REFRESH ENDURA®

REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery

Trial Locations (1)

Unknown

Overland Park

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY

NCT00611403 - Safety and Efficacy Study of Cyclosporine Ophthalmic Emulsion in Post-LASIK Patients | Biotech Hunter | Biotech Hunter